Earnings Update: CTEK AB (publ) (STO:CTEK) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

It's been a pretty great week for CTEK AB (publ) (STO:CTEK) shareholders, with its shares surging 15% to kr14.28 in the week since its latest first-quarter results. Revenues of kr213m beat analyst forecasts by4.1%, while the business broke even in terms of statutory earnings per share (EPS). The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Following the latest results, CTEK's three analysts are now forecasting revenues of kr979.2m in 2025. This would be an okay 6.1% improvement in revenue compared to the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of kr971.9m and earnings per share (EPS) of kr0.76 in 2025. Overall, while the analysts have reconfirmed their revenue estimates, the consensus now no longer provides an EPS estimate. This implies that the market believes revenue is more important after these latest results.

Check out our latest analysis for CTEK

There's been no real change to the consensus price target of kr23.00, with CTEK seemingly executing in line with expectations. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values CTEK at kr27.00 per share, while the most bearish prices it at kr17.00. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. For example, we noticed that CTEK's rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 8.2% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 2.4% a year over the past three years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 9.5% annually. So it looks like CTEK is expected to grow at about the same rate as the wider industry.

The Bottom Line

The clear take away from these updates is that the analysts made no change to their revenue estimates for next year, with the business apparently performing in line with their models. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

At least one of CTEK's three analysts has provided estimates out to 2027, which can be seen for free on our platform here.

You can also view our analysis of CTEK's balance sheet, and whether we think CTEK is carrying too much debt, for free on our platform here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.